07.04.2010

Marco Polo Pharmaceuticals and Biocortech Sign Licensing Agreement to Develop BC-19 in Treatment Resistant Depression 

Marco Polo Pharmaceuticals has obtained rights to develop Biocortech’s BC-19 for treatment-resistant depression. The story was covered by Genetic Engineering News, a site that covers emerging technology and drug discovery news. Genetic Engineering News is a very relevant site for Marco Polo Pharmaceuticals as it will reach a large amount of key pharmaceutical industry personnel who may be interested in the development of BC-19.

Coverage

Genetic Engineering News

RealWire Influence RatingReadership: 143,000

Marco Polo Takes Over Biocortech’s Antidepressant for Treatment-Resistant Disease

Genetic Engineering News (GEN) is an integrated media publication, available in both print and online. GEN's comprehensive coverage includes industry-standard tutorials and technical articles in bio-processing, essays, and drug discovery; feature articles on emerging technologies; product roundups and regional bio-focus articles on biotech hotbeds; and reports from key scientific and industry meetings. 

---